[go: up one dir, main page]

WO1999043660A1 - Carboxamides 1,4-dihydro-4-oxonicotiniques substitues; ligands des recepteurs gaba du cerveau - Google Patents

Carboxamides 1,4-dihydro-4-oxonicotiniques substitues; ligands des recepteurs gaba du cerveau Download PDF

Info

Publication number
WO1999043660A1
WO1999043660A1 PCT/US1999/004303 US9904303W WO9943660A1 WO 1999043660 A1 WO1999043660 A1 WO 1999043660A1 US 9904303 W US9904303 W US 9904303W WO 9943660 A1 WO9943660 A1 WO 9943660A1
Authority
WO
WIPO (PCT)
Prior art keywords
lower alkyl
compound according
carboxamide
alkyl
dihydro
Prior art date
Application number
PCT/US1999/004303
Other languages
English (en)
Inventor
Robert W. Desimone
Charles Manly
Original Assignee
Neurogen Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corporation filed Critical Neurogen Corporation
Priority to AU28811/99A priority Critical patent/AU2881199A/en
Publication of WO1999043660A1 publication Critical patent/WO1999043660A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to substituted 1 , 4-d ⁇ hydro-4- oxonicotimc carboxamides and specifically to such compounds that bind to GABAa receptors.
  • This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating anxiety, sleep and seizure disorders, and overdoses of benzodiazepme-type drugs, and enhancing alertness.
  • ⁇ -Ammobutyric acid (GABA) is regarded as one of the manor inhibitory ammo acid transmitters m the mammalian brain. Over 40 years have elapsed since its presence in the brain was demonstrated (Roberts & Frankel, J. Biol.
  • Postsynaptic responses to GABA are mediated through alterations m chloride conductance that generally, although not invariably, lead to hyperpolarization of the cell.
  • Recent investigations have indicated that the complex of proteins associated with postsynaptic GABA responses is a major site of action for a number of structurally unrelated compounds capable of modifying postsynaptic responses to GABA.
  • Drugs that interact at the GABAa receptor can possess a spectrum of pharmacological activities depending on their abilities to modify the actions of GABA.
  • 1,4-Benzodiazepines such as diazepam, flurazepam, and triazola continue to be among the most widely used as anxiolytics, sedative-hypnotics, muscle relaxants, and anticonvulsants .
  • a number of these compounds are extremely potent drugs; such potency indicates a site of action with a high affinity and specificity for individual receptors.
  • those compounds possessing activity which enhance the effect of GABA are called agonists
  • those compounds which decrease the effect of GABA are called inverse agonists
  • those compounds which block the effect of GABA are called antagonists.
  • the GABAa receptor subunits have been cloned from bovine and human cDNA libraries (Schoenfield et al . , 1988; Duman et al.,_ 1989). A number of distinct cDNAs were identified as subunits of the GABAa receptor complex by cloning and expression. These are categorized into ⁇ , ⁇ , ⁇ , ⁇ , e, and provide a molecular basis for the GABAa receptor heterogeneity and distinctive regional pharmacology (Shiwers et al . , 1980; Levitan et al . , 1989). The ⁇ subunit appears to enable drugs like benzodiazepines to modify the GABA responses (Pritchett et al., 1989). The presence of low Hill coefficients in the binding of ligands to the GABAa receptor indicates unique profiles of subtype specific pharmacological action.
  • This invention provides novel compounds of Formula I which interact with a GABAa binding site, the benzodiazepme receptor.
  • the invention provides compounds useful in the diagnosis and treatment of anxiety, sleep, and seizure disorders, overdose with benzodiazepme drugs and for enhancement of memory.
  • the invention also provides pharmaceutical compositions comprising compounds of Formula I. Accordingly, a broad embodiment of the invention is directed to compounds of Formula I :
  • R n hydrogen or C ⁇ -C 6 alkyl
  • Ri is lower alkyl
  • R is hydrogen or lower alkyl
  • R l and R2 together represent a 2 , 3 , or 4 carbon alkylene moiety that together with the pyridone ring to which they are attached form a 5, 6, or 7 membered oxo-substituted carbocyclic ring where each carbon atom of said alkylene moiety is optionally substituted with halogen, hydroxy, C ⁇ -C 6 alkyl, C ⁇ -C 6 alkoxy, ammo, mono- or d ⁇ (C ⁇ - C 6 ) alkylammo, or trifluoromethyl ; and W is lower alkyl optionally substituted with one or two groups selected from halogen, hydroxy, lower alkoxy, amino, or mono- or dialkyl ammo where each alkyl portion is independently lower alkyl; or W is aryl, arylalkyl, or heteroaryl , where the ring portion of each is optionally substituted with one or two groups
  • R3 and R 4 are the same or different and represent hydrogen or lower alkyl .
  • These compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors. These compounds are therefore useful in the diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory.
  • novel compounds encompassed by the instant invention can be described by general Formula I set forth above or the pharmaceutically acceptable non-toxic salts thereof.
  • Preferred compounds of Formula I are those where R n is hydrogen.
  • Other preferred compounds of Formula I are those where W is mono- or disubstituted phenyl or benzyl.
  • Preferred phenyl and benzyl substituents include halogen, preferably fluoro, chloro and bromo, C ⁇ -C 2 alkyl, Ci-C 6 alkylamino (Ci- C 6 ) alkyl, more preferably methylamino (C x -C 2 ) alkyl groups, and C ⁇ -C 2 alkoxy.
  • W is thiazolyl or pyridyl substituted with one or two groups selected from C ⁇ -C 6 alkoxy, halogen, preferably chloro and fluoro, and 1- or 2-methylaminoethyl .
  • the present invention also encompasses compounds of Formula II
  • W is lower alkyl optionally substituted with one or two groups selected from halogen, hydroxy, lower alkoxy, amino, or mono- or dialkyl amino where each alkyl portion is independently lower alkyl; or
  • W is aryl, arylalkyl, or heteroaryl, where the ring portion of each is optionally substituted with one or two groups independently selected from halogen, trifluoromethyl , cyano, hydroxy, lower alkyl, lower alkoxy, amino, mono or dialkylamino where each alkyl portion is lower alkyl, O 99/43660
  • More preferred compounds of Formula II are where W is lower alkyl or aryl, arylakyl, or heteroaryl, where each aryl is optionally substituted with one or two groups independently selected from halogen, lower alkyl, lower alkoxy, or methylaminoalkyl where each alkyl portion is lower alkyl.
  • W is aryl optionally substituted with one or two groups independently selected from fluorine, methyl, methoxy, or ethoxy.
  • W is C ⁇ -C 6 alkyl, optionally substituted with halogen, amino, or mono- or di(C 1 -C 6 ) alkyl amino.
  • the present invention encompasses compounds of Formula III , i . e , compounds where Ri and R2 together represent a 3 -carbon alkylene moiety that together with the pyridone ring to which they are attached form a 6-membered oxo- substituted carbocyclic ring :
  • R a is hydrogen, halogen, hydroxy, C ⁇ -C 6 alkyl , C ⁇ -C 6 alkoxy, amino, mono- or di (C ⁇ -C 6 ) alkylamino , or trif luoromethyl ;
  • R b is hydrogen, halogen, hydroxy, C ⁇ -C 6 alkyl, C ⁇ -C 6 alkoxy, amino, mono- or di (C ⁇ -C 6 ) alkylamino, or trifluoromethyl ;
  • W is lower alkyl optionally substituted with one or two groups selected from halogen, hydroxy, lower alkoxy, amino, or mono- or dialkyl amino where each alkyl portion is independently lower alkyl; or W is aryl, arylalkyl, or heteroaryl, where the ring portion of each is optionally substituted with one or two groups independently selected from halogen, trifluoromethyl, cyano, hydroxy, lower alkyl, lower alkoxy, amino, mono or dialkylamino where each alkyl portion is lower alkyl, or methylaminoalkyl where each alkyl portion is lower alkyl; or
  • R3 and R 4 are the same or different and represent hydrogen or lower alkyl.
  • Preferred compounds of the invention are those of Formula III where R a and R b are independently hydrogen C ⁇ -C 6 alkyl, or halogen. More preferably, only one of R a and R b maybe a non- hydrogen group selected from C ⁇ -C 6 alkyl or halogen, preferably chloro or fluoro. Still other preferred compounds of Formula III are those where R a is methyl or, more preferably, hydrogen. Other more preferred compounds of Formula III are where W is alkyl or aryl, arylakyl, or heteroaryl, where each aryl is optionally substituted with one or two groups independently selected from halogen, lower alkyl, lower alkoxy, or methylaminoalkyl where each alkyl portion is lower alkyl .
  • R5 and R6 are the same or different and represent hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, amino, mono or dialkylamino where each alkyl portion is lower alkyl, or methylaminoalkyl where each alkyl portion is lower alkyl .
  • R5 and RQ are the same or different and represent hydrogen, halogen, lower alkyl, or lower alkoxy. — '
  • R5 and R ⁇ together represent 2 , 4-difluoro, 2 , 6-difluoro, 2- fluoro-4-methoxy, 4-methoxy, 2 -fluoro, 4-ethoxy, 3 -fluoro, 3- methyl , and 2-methoxy.
  • preferred compounds of Formula IV are those where R 5 is hydrogen and R s is 2 -fluoro.
  • R a is hydrogen, halogen, hydroxy, C ⁇ -C 6 alkyl, C ⁇ -C 6 alkoxy, amino, mono- or di (C ⁇ -C 6 ) alkylamino, or trifluoromethyl ;
  • X is carbon or nitrogen
  • R5 and Re are the same or different and represent hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, amino, mono or dialkylamino where each alkyl portion is lower alkyl, or methylaminoalkyl where each alkyl portion is lower alkyl .
  • More preferred compounds of Formula V are where X is carbon and R5 and R ⁇ are the same or different and represent hydrogen, halogen, lower alkyl, or lower alkoxy.
  • Even more preferred compounds of Formula V are where X is carbon and R5 is hydrogen and Rg i s hydrogen or 2 -fluoro. Particularly preferred compounds of Formula V are where R 5 is hydrogen and R ⁇ is 2 -fluoro.
  • Still other preferred compounds of the invention are those of Formula VI .
  • R7 is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, amino, mono or dialkylamino where each alkyl portion is lower alkyl, or methylaminoalkyl where each alkyl portion is lower alkyl.
  • More preferred compounds of Formula VI are where R7 is hydrogen, halogen, or lower alkyl.
  • R7 is 4-C1-C3 alkyl, preferably methyl.
  • R a is hydrogen, halogen, hydroxy, C ⁇ -C 6 alkyl, C ⁇ -C 6 alkoxy, amino, mono- or di (C ⁇ -C 6 ) alkylamino, or trifluoromethyl
  • R 7 is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, amino, mono or dialkylamino where each alkyl portion is lower alkyl, or methylaminoalkyl where each alkyl portion is lower alkyl.
  • More preferred compounds of Formula VII are where R7 is hydrogen, halogen, or lower alkyl.
  • An even more preferred compound of Formula VII is where R hydrogen .
  • R8 and R9 are the same or different and represent hydrogen, halogen, cyano, hydroxy, lower alkyl, lower alkoxy,
  • R8 and R9 are the same or different and represent hydrogen, halogen, lower alkyl, or lower alkoxy.
  • R ⁇ and R9 together represent 2,3-difluoro or R 8 is hydrogen and R 9 is 2-fluoro, 4-chloro, or 4- (1-methylaminoethyl) .
  • Highly preferred compounds of Formula VIII are those where R ⁇ is hydrogen and R 9 is 2-fluoro.
  • Still another group of preferred compounds of the invention are represented by Formula IX :
  • R a is hydrogen, halogen, hydroxy, Cx-Ce alkyl, C ⁇ -C 6 alkoxy, amino, mono- or di (C ⁇ -C 6 ) alkylamino, or trifluoromethyl ,-
  • R8 and R9 are the same or different and represent hydrogen, halogen, cyano, hydroxy, lower alkyl, lower alkoxy, amino, mono or dialkylamino where each alkyl portion is lower alkyl, methylaminoalkyl where each alkyl portion is lower alkyl .
  • More preferred compounds of Formula IX are where Rs and R9 are the same or different and represent hydrogen, halogen, lower alkyl, or lower alkoxy.
  • alkyl straight or branched chain alkyl groups having 1-6 carbon atoms, such as, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2- pentyl, isopentyl, neopentyl, hexyl, 2 -hexyl, 3 -hexyl, and 3- methylpentyl .
  • alkoxy straight or branched chain alkoxy groups having 1-6 carbon atoms, such as, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert- butoxy, pentoxy, 2-pentoxy, isopentoxy, neopentoxy, hexoxy, 2- hexoxy, 3 -hexoxy, and 3-methylpentoxy.
  • heteroaryl is meant one or more aromatic ring systems of 5-, 6-, or 7-membered rings containing at least one and up to four heteroatoms selected from nitrogen, oxygen, or sulfur.
  • heteroaryl groups include, for example, thienyl, furanyl , thiazolyl, lmidazolyl, (is) oxazolyl , pyridyl , pynmidmyl , (iso) qumolmyl, napthyridmyl, benzimidazolyl , benzoxazolyl .
  • Preferred heteroaryls are thiazolyl and pyridyl groups that are optionally substituted as described herein.
  • aryl an aromatic carbocyclic group having a single ring (e.g., phenyl), multiple rings (e.g., biphenyl) , or multiple condensed rings in which at least one is aromatic,
  • a preferred aryl group is phenyl that is optionally substituted as described herein.
  • Representative compounds of the present invention include, but are not limited to
  • the compounds in Table I ⁇ 15- the compounds in Table I and their pharmaceutically acceptable acid or base addition salts.
  • the free base can be obtained by basifying a solution of the acid salt.
  • an addition salt, particularly a pharmaceutically acceptable addition salt may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds.
  • Non-toxic pharmaceutically acceptable salts include salts of acids such as hydrochloric, phosphoric, hydrobromic, sulfuric, sulfinic, formic, toluenesulfonic, methanesulfonic, nitric, benzoic, citric, tartaric, maleic, hydroiodic, alkanoic such as acetic, HOOC- (CH2) n-COOH where n is 0-4, and the like.
  • acids such as hydrochloric, phosphoric, hydrobromic, sulfuric, sulfinic, formic, toluenesulfonic, methanesulfonic, nitric, benzoic, citric, tartaric, maleic, hydroiodic, alkanoic such as acetic, HOOC- (CH2) n-COOH where n is 0-4, and the like.
  • acids such as hydrochloric, phosphoric, hydrobromic, sulfuric, sulfinic, formic, toluen
  • the present invention also encompasses the acylated prodrugs of the compounds of Formula I.
  • acylated prodrugs of the compounds of Formula I Those skilled in the art will recognize various synthetic methodologies which may be employed to prepare non-toxic pharmaceutically acceptable addition salts and acylated prodrugs of the compounds encompassed by Formula I .
  • the compounds of Formula I and their salts are suitable for the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs and for enhancement of alertness, both in human and non-human animals and domestic pets, especially dogs and cats and farm animals such as sheep, swine and cattle.
  • the compounds of general Formula I may be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and
  • a pharmaceutical formulation comprising a compound of general Formula I and a pharmaceutically acceptable carrier.
  • One or more compounds of general Formula I may be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants and if desired other active ingredients.
  • the pharmaceutical compositions containing compounds of general Formula I may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.
  • compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol , or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol onooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monoo
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
  • Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl
  • Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
  • compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol , propylene glycol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be sterile injectable solution or
  • a non-toxic parentally acceptable diluent or solvent for example as a solution in 1, 3-butanediol .
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides .
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • the compounds of general Formula I may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter
  • Compounds of general Formula I may be administered parenterally in a sterile medium.
  • the drug depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle.
  • adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.
  • Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5 mg to about 7 g per patient per day) .
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient.
  • the composition may also be added to the animal feed or drinking water. It will be convenient to formulate these animal feed and drinking water compositions with a mullet-dose of the drug so that the animal takes in an appropriate quantity of the composition along with its diet. It will also be convenient to present the composition as a premix for addition to the feed or drinking water.
  • a carboxylic acid is treated with an acid chloride, such as, for example, ethyl chloroformate, in the presence of a base like triethylamme .
  • an acid chloride such as, for example, ethyl chloroformate
  • the resulting mixed anhydride is subsequently treated with an amme to afford the desired amide.
  • N-alkylated compounds i.e., where
  • R -21- R n is C ⁇ -C 6 alkyl
  • R n is C ⁇ -C 6 alkyl
  • the starting materials and various intermediates may be obtained from commercial sources, prepared from commercially available organic compounds, or prepared using well known synthetic methods.
  • a quantity of 150 mg (0.768 mmole, 1.0 eq) of 1,4- dihydro-4-oxo-5-acetyl-6-methyl-3-carboxylic acid is dissolved in 5 ml THF and 1 ml DMF and treated at 0° C with 0.16 ml (1.69 mmole, 2.2 eq) TEA followed by 0.24 ml (1.69 mmole, 2.2 eq) of ethyl chloroformate .
  • the resulting solution is stirred for 30 min. at which time 150 mg (1.69 mmole, 2.2 eq) of 4-methyl-2- amino-thiazole is added.
  • the solution is allowed to warm to room temperature for 1 hr before the addition of 20 ml of H 2 0.
  • the THF is removed under reduced pressure, and the resulting solid is filtered and washed with H0 and then Et 0.
  • the solid is then slurred in 1 ml EtOH/5 ml 10% NaOH and warmed to 90° C for 10 min., cooled to 0° C, and the pH adjusted to 9.0 with 3N HC1.
  • the crude product is filtered, washed with H0 and then
  • a quantity of 150 mg (0.768 mmole, 1.0 eq) of 1,4- dihydro-4-oxo-5-acetyl-6-methyl-3-carboxylic acid is dissolved in 5 ml THF and 1 ml DMF and treated at 0° C with 0.16 ml (1.69 mmole, 2.2 eq) TEA followed by 0.24 ml (1.69 mmole, 2.2 eq) of ethyl chloroformate .
  • the resulting solution is stirred for 30 min at which time 0.18 ml (1.69 mmole, 2.2 eq) of n-Butyl amine is added.
  • the solution is allowed to warm to room temperature for 1 hr before the addition of 20 ml of H 2 0.
  • Rat cortical tissue is dissected and homogenized in 25 volumes (w/v) of 0.05 M Tris HC1 buffer (pH 7.4 at 4 °C) .
  • the tissue homogenate is centrifuged in the cold (4°) at 20,000 x g for 20'.
  • the supernatant is decanted and the pellet is rehomogenized in the same volume of buffer and again centrifuged at 20,000 x g.
  • the supernatant is decanted and the pellet is frozen at -20°C overnight.
  • the pellet is then thawed and rehomogenized in 25 volume (original wt/vol) of buffer and the procedure is carried out twice.
  • the pellet is finally resuspended in 50 volumes (w/vol of 0.05 M Tris HC1 buffer (pH 7.4 at 40°C) .
  • Incubations contain 100 ml of tissue homogenate, 100 ml of radioligand 0.5 nM ( 3 H-R015-1788 [ 3 H-Flumazenil] specific activity 80 Ci/mmol) , drug or blocker and buffer to a total volume of 500 ml. Incubations are carried for 30 min at 4°C then are rapidly filtered through GFB filters to separate free
  • Tris HC1 buffer pH 7.4 at 4°C
  • 1.0 mM diazepam is added to some tubes to determine nonspecific binding.
  • Data are collected in triplicate determinations, averaged and % inhibition of total specific binding is calculated.
  • Total Specific Binding Total - Nonspecific.
  • the amounts of unlabeled drugs is varied and total displacement curves of binding are carried out.
  • Data are converted to IC50 or Ki .
  • the Ki's of the compounds described herein are generally less than 1 ⁇ M.
  • the following assay may be used to determine if the compounds of the invention are agonists, antagonists, or inverse agonists, and, therefore, their specific pharmaceutical utility.
  • the following assay can be employed to determine specific GABAa receptor activity.
  • Assays are carried out as described in White and Gurley (NeuroReport 6.: 1313-1316, 1995) and White, Gurley, Hartnett, Stirling, and Gregory (Receptors and Channels 3_: 1-5, 1995) with modifications.
  • Xenopus Laevis oocytes are enzymatically isolated and injected with non-polyadenylated cRNA mixed in a ratio of 4:1:4 for human derived ⁇ , ⁇ , and ⁇ subunits, respectively. For each subunit combination, sufficient message is injected to result in current amplitudes of >10 nA when 1 ⁇ M GABA is applied.
  • Electrophysiological recordings are carried out using the two electrode voltage-clamp technique at a membrane holding potential of -70 mV.
  • Compounds are evaluated against a GABA concentration that evokes ⁇ 10% of the maximal evokable GABA current.
  • Each oocyte is exposed to increasing concentrations of compound in order to evaluate a concentration/effect relationship.
  • Compound efficacy is expressed as a percent-change in current

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés représentés par la formule (a) ou leurs sels non toxiques pharmaceutiquement acceptables. Dans cette formule, R1 représente alkyle inférieur; R2 représente hydrogène ou alkyle inférieur; ou R1 et R2 représentent une fraction d'alkylène à 2, 3 ou 4 atomes de carbone et forment avec le noyau pyridone auquel ils sont fixés un noyau carbocyclique à 5, 6 ou 7 éléments; et W représente alkyle, aryle, arylalkyle ou hétéroaryle substitués ou non substitués; ou W représente NR3COR4, COR4, CONR3R4 ou CO2R4, dans lesquelles R3 et R4 sont identiques ou différents et représentent hydrogène ou alkyle inférieur. Lesdits composés sont des agonistes, des antagonistes ou des agonistes inverses à haute sélectivité des récepteurs GABAa du cerveau, ou des promédicaments d'agonistes, d'antagonistes ou d'agonistes inverses des récepteurs GABAa du cerveau. Lesdits composés sont utiles dans le diagnostic et le traitement de l'anxiété, des troubles du sommeil, des troubles épileptiques, des surdoses de médicaments à base de benzodiazépine ainsi que pour la stimulation de la mémoire.
PCT/US1999/004303 1998-02-26 1999-02-26 Carboxamides 1,4-dihydro-4-oxonicotiniques substitues; ligands des recepteurs gaba du cerveau WO1999043660A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU28811/99A AU2881199A (en) 1998-02-26 1999-02-26 Substituted 1,4-dihydro-4-oxonicotinic carboxamides: gaba brain receptor ligands

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7602398P 1998-02-26 1998-02-26
US60/076,023 1998-02-26

Publications (1)

Publication Number Publication Date
WO1999043660A1 true WO1999043660A1 (fr) 1999-09-02

Family

ID=22129459

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/004303 WO1999043660A1 (fr) 1998-02-26 1999-02-26 Carboxamides 1,4-dihydro-4-oxonicotiniques substitues; ligands des recepteurs gaba du cerveau

Country Status (3)

Country Link
US (1) US6156898A (fr)
AU (1) AU2881199A (fr)
WO (1) WO1999043660A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077079A3 (fr) * 2000-04-05 2002-04-11 Pharmacia Corp Pyridones polycycliques 4-aryl et heteroaryl substituees utiles pour l'inhibition selective de la cascade de coagulation
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6660885B2 (en) 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6686484B2 (en) 2000-04-17 2004-02-03 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6828338B2 (en) 2000-11-20 2004-12-07 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6875791B2 (en) 2000-04-05 2005-04-05 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
US6906068B1 (en) 1999-05-19 2005-06-14 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4 - triazinones useful as anticoagulants
US6969715B2 (en) 2001-10-03 2005-11-29 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US7105559B2 (en) 2001-10-03 2006-09-12 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2620333A1 (fr) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
EP2258357A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse avec inhibiteur de l'acetylcholinestérase
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
WO2007053596A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (fr) 2006-05-09 2011-10-19 Braincells, Inc. Neurogénèse par modulation de l'angiotensine
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
MX2009002496A (es) * 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026243A1 (fr) * 1996-01-19 1997-07-24 Neurogen Corporation Nouvelles pyrrolecarboxamides fusionnees; une nouvelle classe de ligands de recepteurs gaba dans le cerveau
WO1997034870A1 (fr) * 1996-03-22 1997-09-25 Neurogen Corporation Certains pyrrolecarboxamides fusionnes utilises comme ligands de recepteurs cerebraux gaba
WO1997035539A2 (fr) * 1996-03-27 1997-10-02 Du Pont Pharmaceuticals Company Pyridines et pyrimidines a fusion arylamino

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008220A (en) * 1972-03-15 1977-02-15 Sumitomo Chemical Company, Limited Penicillins
JPS55139389A (en) * 1979-04-19 1980-10-31 Mitsui Toatsu Chem Inc Novel cephalosporin
JPS5573686A (en) * 1978-11-28 1980-06-03 Mitsui Toatsu Chem Inc Novel penicillin
JPS5572195A (en) * 1978-11-28 1980-05-30 Mitsui Toatsu Chem Inc Novel cephalosporin and antibacterial comprising it as active constituent
US4921530A (en) * 1984-11-06 1990-05-01 Monsanto Company Certain 3,5-pyridine dicarboxylates, their thio analogues having herbicidal activity
FR2612189B1 (fr) * 1987-03-13 1989-06-23 Roussel Uclaf Nouveaux derives de la pyridine, leur procede de preparation et les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions les renfermant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026243A1 (fr) * 1996-01-19 1997-07-24 Neurogen Corporation Nouvelles pyrrolecarboxamides fusionnees; une nouvelle classe de ligands de recepteurs gaba dans le cerveau
WO1997034870A1 (fr) * 1996-03-22 1997-09-25 Neurogen Corporation Certains pyrrolecarboxamides fusionnes utilises comme ligands de recepteurs cerebraux gaba
WO1997035539A2 (fr) * 1996-03-27 1997-10-02 Du Pont Pharmaceuticals Company Pyridines et pyrimidines a fusion arylamino

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6906068B1 (en) 1999-05-19 2005-06-14 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4 - triazinones useful as anticoagulants
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6870056B1 (en) 1999-05-19 2005-03-22 Pharmacia Corporation Substitituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6660885B2 (en) 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
US6852761B2 (en) 2000-03-13 2005-02-08 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
US6693121B2 (en) 2000-04-05 2004-02-17 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
US6875791B2 (en) 2000-04-05 2005-04-05 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
WO2001077079A3 (fr) * 2000-04-05 2002-04-11 Pharmacia Corp Pyridones polycycliques 4-aryl et heteroaryl substituees utiles pour l'inhibition selective de la cascade de coagulation
US6916847B2 (en) 2000-04-05 2005-07-12 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
US6686484B2 (en) 2000-04-17 2004-02-03 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
US6828338B2 (en) 2000-11-20 2004-12-07 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
US6969715B2 (en) 2001-10-03 2005-11-29 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
US7105559B2 (en) 2001-10-03 2006-09-12 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade

Also Published As

Publication number Publication date
AU2881199A (en) 1999-09-15
US6156898A (en) 2000-12-05

Similar Documents

Publication Publication Date Title
US6156898A (en) Substituted 1,4-dihydro-4-oxonicotinic carboxamides; GABA brain receptor ligands
US6380209B1 (en) 4-(4-piperidylmethylamino) substituted heteroaryl fused pyridines: GABA brain receptor ligands
US6646124B2 (en) Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands
US6423711B1 (en) Heterocyclic amino substituted heteroaryl fused pyridines; GABA brain receptor ligands
AU754716B2 (en) Amide derivatives and nociceptin antagonists
DE60029235T2 (de) Fab-i-hemmer
US6576644B2 (en) Quinoline inhibitors of cGMP phosphodiesterase
US6451809B2 (en) Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands
US6414147B1 (en) 2-amino-9-alkylpurines: GABA brain receptor ligands
EP1056724B1 (fr) Carboxamides cycloalkyl-4-oxonicotiniques substitues; ligands des recepteurs gaba du cerveau
JPH06502639A (ja) 特定のイミダゾキノキサリン；新種のｇａｂａ脳受容体リガンド
JPH06504054A (ja) 特定アミノメチルフェニルイミダゾール誘導体、新種のドーパミン受容体サブタイプの特定リガンド
AU753800B2 (en) Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
EP1107966B1 (fr) Oxo-pyridoimidazole-carboxamides: ligands du recepteur cerebral gaba
JP4189029B2 (ja) 抗けいれん剤としての未置換および置換ｎ−（ピロール−１−イル）ピリジンアミンの使用
MXPA00008364A (en) Substituted cycloalkyl-4-oxonicotinic carboxamides;gaba brain receptor ligands
MXPA01001991A (en) Oxo-pyridoimidazole-carboxamides:gaba brain receptor ligands
MXPA00001598A (en) Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase